What is Sanaria?
Founded in 2003 and headquartered in Rockville, Maryland, Sanaria Inc. operates at the intersection of advanced immunology and public health. The company is primarily focused on the research, development, and manufacturing of whole-parasite vaccines designed to provide high-level protection against malaria. By leveraging proprietary manufacturing processes and clinical trial frameworks, Sanaria has positioned itself as a critical player in the biotechnology landscape, addressing one of the most persistent challenges in global infectious disease control. Its market position is defined by a rigorous commitment to clinical efficacy and the scaling of complex biological production, which requires substantial, sustained financial backing to navigate the regulatory and scientific hurdles inherent in vaccine development.
How much funding has Sanaria raised?
Sanaria has raised a total of $2.1M across 2 funding rounds:
Debt
$1M
Debt
$1.1M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.1M led by PPP
Key Investors in Sanaria
PPP
Public-Private Partnership
What's next for Sanaria?
With the recent infusion of capital, Sanaria is well-positioned to accelerate its clinical trial programs and optimize its manufacturing infrastructure. The strategic focus will likely shift toward scaling production capabilities to meet potential global demand, while simultaneously navigating the complex regulatory pathways required for international vaccine deployment. As the company moves beyond its current development phase, the emphasis will remain on demonstrating the durability and safety of its vaccine candidates. Investors and stakeholders will be monitoring the firm's ability to translate its scientific breakthroughs into scalable, public-health-ready solutions, ensuring that the recent financing serves as a catalyst for long-term impact in the fight against malaria.
See full Sanaria company page
